Acadia Pharmaceuticals | ACAD - Gross Profit On Sales


Acadia Pharmaceuticals reported $257.76M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 257.76M 778K Dec/2025
ALKERMES USD 338.34M 72.51M Dec/2025
Alnylam Pharmaceuticals USD 829.31M 219.56M Dec/2025
Biogen USD 1.65B 34.6M Dec/2025
BioMarin Pharmaceutical USD 713.01M 81.81M Dec/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Cara Therapeutics USD 2.57M 1.11M Mar/2025
Corcept Therapeutics USD 199.58M 3.46M Dec/2025
Cytokinetics USD 17.76M 15.82M Dec/2025
Eisai JPY 168.85B 17.02B Dec/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Incyte USD 1.17B 217.51M Mar/2026
J&J USD 17.24B 642M Mar/2026
Moderna USD 226M 583M Dec/2025
Neurocrine Biosciences USD 787.9M 7M Dec/2025
Pfizer USD 3.54B 7.61B Sep/2025
Prothena USD 21K 2.39M Dec/2025
PTC Therapeutics USD 148.38M 39.31M Dec/2025
Sarepta Therapeutics USD 43.55M 204.36M Dec/2025
Ultragenyx Pharmaceutical USD 178M 46.06M Dec/2025
Vanda Pharmaceuticals USD 50.6M 5.5M Dec/2024
Vertex Pharmaceuticals USD 2.72B 62.4M Dec/2025